4.6 Article

Mesorectal nodal metastasis with seminal vesicle invasion in biochemically recurrent prostate cancer

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Urology & Nephrology

Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surgery

Sophie Knipper et al.

Summary: This study evaluated the oncological outcomes of salvage PSMA-RGS in patients with recurrent oligometastatic prostate cancer and identified predictive preoperative factors for improved outcomes. The results showed that the 3-month and 2-year tumor survival rates were 32% and 58%, respectively. Preoperative PSA, number of PSMA-avid lesions, and localization of lesions were independent predictors of biochemical recurrence after PSMA-RGS.

EUROPEAN UROLOGY (2023)

Article Radiology, Nuclear Medicine & Medical Imaging

Effect of 18F-DCFPyL PET/CT on the Management of Patients with Recurrent Prostate Cancer: Results of a Prospective Multicenter Registry Trial

Ur Metser et al.

Summary: The study indicates that PSMA PET can help detect additional sites of disease compared to conventional imaging in men with biochemical failure and suspected low-volume metastatic prostate cancer, leading to frequent changes in management strategies.

RADIOLOGY (2022)

Article Radiology, Nuclear Medicine & Medical Imaging

Impact of 18F-DCFPyL PET on Staging and Treatment of Unfavorable Intermediate or High-Risk Prostate Cancer

Adriano Basso Dias et al.

Summary: This study compared the performance of F-18-DCFPyL PET/CT or PET/MRI with bone scan and CT with or without multiparametric MRI in the initial staging of prostate cancer. The results showed that PET had better performance in detecting pelvic nodal and distant metastases compared to conventional imaging and changed treatment plans for some patients.

RADIOLOGY (2022)

Article Radiology, Nuclear Medicine & Medical Imaging

PSMA uptake on [68Ga]-PSMA-11-PET/CT positively correlates with prostate cancer aggressiveness

Mengxia Chen et al.

Summary: This study validates the relationship between PSMA uptake and prostate cancer aggressiveness, and highlights its role in the evaluation of clinically significant PCa and risk stratification. SUVmax and SUVmean can be utilized as parameters for the detection of csPCa and risk classification.

QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

Article Oncology

Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study

Michael J. Morris et al.

Summary: F-18-DCFPyL-PET/CT demonstrated good localization performance in patients with BCR, providing meaningful and actionable information that led to a change in management for 63.9% of patients.

CLINICAL CANCER RESEARCH (2021)

Article Urology & Nephrology

A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY)

Kenneth J. Pienta et al.

Summary: The study aimed to evaluate the diagnostic performance of F-18-DCFPyL positron emission tomography/computerized tomography in detecting metastatic sites of prostate cancer. The results showed high specificity and positive predictive value, but moderate sensitivity.

JOURNAL OF UROLOGY (2021)

Article Oncology

Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high risk prostate cancer: Long term results from a prospective clinical trial

Rachel M. Glicksman et al.

Summary: The study demonstrates that EPNI and a simultaneous hypofractionated prostate boost combined with long-term ADT for high-risk prostate cancer resulted in acceptable 10-year biochemical control and survival with low grade >3 toxicity.

RADIOTHERAPY AND ONCOLOGY (2021)

Article Oncology

Establishing a Provincial Registry for Recurrent Prostate Cancer: Providing Access to PSMA PET/CT in Ontario, Canada

Sympascho Young et al.

Summary: PSMA PET/CT imaging is becoming a standard of care for prostate cancer staging and recurrence, but its availability varies globally. In Canada, PSMA-based radiopharmaceuticals are still considered investigational new drugs, with funding decisions made by provincial health ministries.

FRONTIERS IN ONCOLOGY (2021)

Article Oncology

Increased Frequency of Mesorectal and Perirectal LN Involvement in T4 Prostate Cancers

Ibrahim Abu-Gheida et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)

Article Radiology, Nuclear Medicine & Medical Imaging

Revisiting Prostate Cancer Recurrence with PSMA PET: Atlas of Typical and Atypical Patterns of Spread

Felipe G. Barbosa et al.

RADIOGRAPHICS (2019)

Article Radiology, Nuclear Medicine & Medical Imaging

Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT

Matthias Eiber et al.

JOURNAL OF NUCLEAR MEDICINE (2018)

Article Endocrinology & Metabolism

See the unseen: Mesorectal lymph node metastases in prostate cancer

Sameh Hijazi et al.

PROSTATE (2016)

Article Radiology, Nuclear Medicine & Medical Imaging

PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions

A. Afshar-Oromieh et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)

Article Emergency Medicine

Logistic Regression: A Brief Primer

Jill C. Stoltzfus

ACADEMIC EMERGENCY MEDICINE (2011)

Article Oncology

Definition and delineation of the clinical target volume for rectal cancer

Sarah Roels et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)

Article Gastroenterology & Hepatology

Mesorectal lymph nodes: Their location and distribution within the mesorectum

B Topor et al.

DISEASES OF THE COLON & RECTUM (2003)